Skip to content

The Effects of Whole-Body Vibration Training on Clinical and Functional Outcomes in Individuals Diagnosed With Interstitial Lung Disease

The Effects of Whole-Body Vibration Training on Clinical and Functional Outcomes in Individuals Diagnosed With Interstitial Lung Disease: A Randomized Controlled Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07709260
Enrollment
26
Registered
2026-07-16
Start date
2026-01-15
Completion date
2026-07-01
Last updated
2026-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial Lung Diseases

Keywords

Interstitial Lung Disease, Whole-Body Vibration Training, Exercise

Brief summary

This randomized controlled trial aims to investigate the clinical and functional effects of Whole Body Vibration (WBV) training when added to a standard pulmonary rehabilitation (PR) program in patients with fibrotic interstitial lung disease (ILD). Participants aged between 40 and 80 years with confirmed ILD diagnosis will be randomly assigned to two groups: (1) PR only (control), and (2) PR + WBV (intervention). The program will last for 8 weeks, with supervised sessions twice per week. Primary outcome measures include pulmonary function (FEV₁, FVC), exercise capacity (6-minute walk test), dyspnea (mMRC and Borg scale), arterial blood gas analysis, depression level (Beck Depression Inventory), and disease-specific quality of life (St. George's Respiratory Questionnaire). WBV will be performed using a side-alternating vibration platform starting at 10 Hz and progressively increased up to 24-26 Hz over 8 weeks. All procedures will follow ATS/ERS guidelines. This study is conducted at the Chest Diseases Department of Sultan Abdulhamid Han Training and Research Hospital in Istanbul under the supervision of a multidisciplinary team. The goal is to determine whether WBV offers additional benefit in improving functional outcomes, respiratory performance, and quality of life in ILD patients undergoing PR.

Detailed description

1. Study Background and Aim Interstitial lung disease (ILD) is characterized by inflammation and progressive fibrosis, leading to restrictive respiratory patterns, exertional dyspnea, and reduced exercise capacity. While pulmonary rehabilitation (PR) is a cornerstone of clinical management, data regarding the efficacy of Whole-Body Vibration Training (WBVT) in this population remain limited. The aim of this study is to investigate the effectiveness of WBVT applied in addition to a routine PR program consisting of respiratory muscle training, peripheral muscle training, and aerobic exercise in individuals with ILD. This randomized controlled trial comprehensively evaluates the clinical and functional effects of WBVT, focusing on lung functions, functional exercise capacity, gas exchange capacity via arterial blood gas analysis, multidimensional dyspnea levels, psychological status, and quality of life. 2. Study Design and Population This is a two-arm, prospective, randomized controlled trial conducted at the Pulmonary Rehabilitation Unit of the Pulmonology Department at Istanbul Sultan Abdülhamid Han Training and Research Hospital. Patients aged 40-80 years diagnosed with ILD will be screened. Following cardiovascular suitability clearance by a cardiologist, participants will be randomly assigned to either the Control Group (PR alone) or the Study Group (PR + WBVT) using a computer-based block randomization method. All procedures align with the Declaration of Helsinki, and written informed consent will be obtained. 3. INTERVENTIONS 3.1. Control Group (CG) - Standard Pulmonary Rehabilitation Participants in the control group will receive a supervised standard pulmonary rehabilitation (PR) program twice a week for 8 weeks. This program includes active cycle of breathing, diaphragmatic, and pursed-lip breathing techniques, alongside three structured training modalities. First, Inspiratory Muscle Training will be performed using the Powerbreathe Medic Plus (gray) device twice weekly, with the initial load set at a rating of perceived exertion (RPE) of 3-4 on the Modified Borg Scale and increased by 5-10% weekly (5 breaths × 6 sets). Second, Peripheral Muscle Training will target the quadriceps, shoulder flexors, and shoulder abductors at an RPE of 3-4, structured as 2 sets of 8 repetitions. Third, the Aerobic Exercise Program will be conducted on a cycle ergometer twice weekly for 21 minutes (3-minute warm-up, 15-minute target-intensity, and 3-minute cool-down) at 60-80% of the target heart rate calculated via the Karvonen formula, with pedal resistance adjusted weekly by 5-10% to maintain an RPE of 3-4. 3.2. Study Group (SG) - Pulmonary Rehabilitation + Whole-Body Vibration Training (WBVT)Participants in the study group will receive the identical 8-week standard PR program described for the control group, combined with a supervised WBVT protocol performed twice a week using the Power Plate ProXG10 Acceleration Pro series platform. During WBVT, participants stand barefoot on the platform with slight knee flexion (\ 150°). Each session begins with a 5-minute warm-up (low-intensity treadmill walking/cycling and stretching) and concludes with a 5-minute cool-down consisting of static stretching. For the first 4 weeks, WBVT will be applied as 2 sets of 3 minutes with 2-minute rest intervals, starting at a frequency of 10 Hz and increasing by 2-3 Hz weekly based on tolerance. From week 5 through week 8, the training volume will increase to 3 sets of 3 minutes, progressively raising the frequency to reach a target of 24-26 Hz. The vibration amplitude will be kept constant at approximately 4-6 mm throughout the entire 8-week intervention. 4. STATISTICAL METHODOLOGY Sample Size and Statistical Analysis Based on a two-tailed independent samples t-test for the primary outcome, assuming a significance level of $\\alpha = 0.05$, a statistical power ($1-\\beta$) of 0.80, and an expected effect size of Cohen's $d = 1.15$ calculated via G\*Power 3.1, a minimum sample size of 26 participants (13 per group) is required. To account for a potential 15% attrition rate, additional participants will be recruited. Statistical analysis will be performed using IBM SPSS Statistics V26.0 software. Normality will be assessed with the Shapiro-Wilk test. Continuous variables will be analyzed using Mixed Design ANOVA or appropriate parametric/non-parametric tests (Student's t-test, Paired t-test, Mann-Whitney U, Wilcoxon signed-rank) depending on the distribution of the data, with statistical significance set at $p \< 0.05$.

Interventions

DEVICEInspiratory Muscle Training

Inspiratory muscle training performed using the PowerBreathe Medic Plus device twice weekly for 8 weeks. Training follows a 5 breaths × 6 sets protocol, with the initial load set to achieve an RPE of 3-4 on the Modified Borg Scale. Load is increased weekly by 5-10% according to patient tolerance.

Resistance exercises targeting the quadriceps, shoulder flexors, and shoulder abductors performed at an RPE of 3-4, for 2 sets of 8 repetitions. Sessions occur twice weekly for 8 weeks under supervision.

BEHAVIORALAerobic Exercise Training (Cycle Ergometer)

Aerobic exercise performed on a cycle ergometer at 60-80% of the target heart rate calculated using the Karvonen formula. Each session includes 3 minutes warm-up, 15 minutes active exercise, and 3 minutes cool-down (total 21 minutes). Resistance is adjusted weekly by 5-10% to maintain an RPE of 3-4. Conducted twice weekly for 8 weeks.

Whole-body vibration training performed using the Power Plate ProXG10 Acceleration Pro series device, twice weekly for 8 weeks. Sessions include warm-up, vibration training, and cool-down components. Vibration begins at 10 Hz and increases gradually by 2-3 Hz each week, reaching 24-26 Hz by week 8. Amplitude is maintained at 4-6 mm. WBVT is applied as 2 sets × 3 minutes initially, with 2 minutes rest between sets, progressing to 3 sets × 3 minutes from week 5 onward. Participants stand barefoot with slight knee flexion (approximately 150°) while maintaining an RPE of 3-4.

Sponsors

Istinye University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

The study uses a single-blind design. Participants with interstitial lung disease are randomized into two parallel groups. The control group receives pulmonary rehabilitation only, including inspiratory muscle training, strengthening, and aerobic exercise twice weekly for 8 weeks. The experimental group receives the same rehabilitation program plus whole body vibration on a side-alternating platform (10-26 Hz). Outcome assessors are blinded to group allocation. Primary outcomes are changes in six-minute walk distance, pulmonary function (FVC, FEV₁, FEV₁/FVC), and arterial blood gases (PaO₂, PaCO₂, SaO₂, pH, HCO₃-). Secondary outcomes include dyspnea (mMRC, Borg scale), depression (BDI), and quality of life (SGRQ).

Intervention model description

Participants with fibrotic interstitial lung disease (ILD), aged between 40 and 80 years, will be randomly assigned to two parallel groups using block randomization. The control group will receive a supervised pulmonary rehabilitation (PR) program consisting of inspiratory muscle training, peripheral muscle strengthening, and aerobic exercise. The intervention group will receive the same PR program plus whole body vibration (WBV) training delivered on a side-alternating vibration platform. Both groups will participate in supervised sessions twice per week for 8 weeks at the Chest Diseases Department of Sultan Abdulhamid Han Training and Research Hospital in Istanbul. The study follows a single-blind design in which outcome assessors will be blinded to group allocation. Clinical and functional outcomes, including pulmonary function tests, exercise capacity, arterial blood gases, dyspnea, depression, and quality of life, will be measured before and after the intervention to compare the

Eligibility

Sex/Gender
ALL
Age
40 Months to 80 Months
Healthy volunteers
No

Inclusion criteria

* Ages 40 to 80 years * Diagnosis of fibrotic interstitial lung disease confirmed by a multidisciplinary council (e.g., idiopathic pulmonary fibrosis, idiopathic nonspecific interstitial pneumonia, sarcoidosis, or other fibrotic patterns) * Receiving stable pharmacological treatment for at least 3 months (e.g., antifibrotic or immunosuppressive therapy) * No acute exacerbation or upper respiratory tract infection within the past 4 weeks * Able to safely participate in pulmonary rehabilitation and whole-body vibration training as determined by clinical evaluation

Exclusion criteria

* Pulmonary hypertension with systolic pulmonary artery pressure \>65 mmHg * Severe cardiovascular disease (e.g., uncontrolled hypertension, congestive heart failure, recent myocardial infarction) * Advanced renal or hepatic failure * Balance disorders preventing safe standing on a vibration platform * Severe musculoskeletal limitations (e.g., advanced arthritis, severe osteoporosis, high fall risk) * Advanced cognitive impairment or dementia * Severe psychiatric disorders (e.g., severe depression or anxiety) * Neurological diseases interfering with participation or test performance * Participation in a pulmonary rehabilitation program during the study or within the past 6 months * Pregnancy or breastfeeding * Uncontrolled metabolic diseases (e.g., advanced diabetes, uncontrolled thyroid dysfunction) * Vestibular system disorders * Active malignancy * Presence of a pacemaker or other contraindicated implanted electronic devices

Design outcomes

Primary

MeasureTime frameDescription
Change in Six-Minute Walk DistanceBaseline and after 8 weeksFunctional exercise capacity assessed with the six-minute walk test according to ATS guidelines. Distance in meters will be recorded.

Secondary

MeasureTime frameDescription
Forced Vital Capacity (FVC, % predicted)Baseline and 8 weeksPulmonary function will be evaluated by spirometry according to ATS/ERS standards. FVC (% predicted) will be recorded.
Forced Expiratory Volume in 1 Second (FEV1, % predicted)Baseline and 8 weeksSpirometry measurement of FEV1 (% predicted).
FEV1/FVC Ratio (%)Baseline and 8 weeksRatio of forced expiratory volume in one second to forced vital capacity.
Partial Pressure of Oxygen (PaO2, mmHg)Baseline and 8 weeksResting arterial blood gas analysis, measuring oxygen tension (PaO2).
Partial Pressure of Carbon Dioxide (PaCO2, mmHg)Baseline and 8 weeksResting arterial blood gas analysis measuring PaCO2.
Blood pHBaseline and 8 weeksArterial blood gas analysis measuring systemic pH.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 18, 2026